Saroglitazar, a PPAR-α/γ Agonist, for Treatment of NAFLD: A Randomized Controlled Double-Blind Phase 2 Trial.

Samer GawriehMazen NoureddinNicole LooRizwana MohseniVivek AwastyKenneth CusiKris V KowdleyMichelle LaiEugene SchiffDeven ParmarPankaj PatelNaga P Chalasani

Published in: Hepatology (Baltimore, Md.) (2021)

Saroglitazar 4 mg significantly improved ALT, LFC, insulin resistance, and atherogenic dyslipidemia in participants with NAFLD/NASH. (ClinicalTrials.gov identifier: NCT03061721.).

Keyphrases

insulin resistance
double blind
adipose tissue
clinical trial
metabolic syndrome
high fat diet
skeletal muscle
placebo controlled
polycystic ovary syndrome
study protocol
high fat diet induced
combination therapy
fatty acid
phase iii
glycemic control
low density lipoprotein